Susan Little

Susan Little

University of California, San Diego

H-index: 75

North America-United States

About Susan Little

Susan Little, With an exceptional h-index of 75 and a recent h-index of 37 (since 2020), a distinguished researcher at University of California, San Diego, specializes in the field of HIV, prevention, treatment, molecular epidemiology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Quantifying how single dose Ad26. COV2. S vaccine efficacy depends on Spike sequence features

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study

Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial

Assessing the reliability of the CD4 depletion model in the presence of Ending the HIV Epidemic initiatives

Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping

Comparative analysis of pre-existing HIV drug resistance mutations in proviral DNA using next-generation sequencing and routine HIV RNA genotyping.

Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection

Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States

Susan Little Information

University

Position

___

Citations(all)

23826

Citations(since 2020)

6075

Cited By

19715

hIndex(all)

75

hIndex(since 2020)

37

i10Index(all)

218

i10Index(since 2020)

154

Email

University Profile Page

Google Scholar

Susan Little Skills & Research Interests

HIV

prevention

treatment

molecular epidemiology

Top articles of Susan Little

Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study

The Lancet HIV

2024/3/1

Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial

Clinical Infectious Diseases

2023/8/15

Assessing the reliability of the CD4 depletion model in the presence of Ending the HIV Epidemic initiatives

AIDS

2023/8/1

Brief Report: Comparative Analysis of Pre-existing HIV Drug Resistance Mutations in Proviral DNA Using Next-Generation Sequencing and Routine HIV RNA Genotyping

JAIDS Journal of Acquired Immune Deficiency Syndromes

2023/7/1

Comparative analysis of pre-existing HIV drug resistance mutations in proviral DNA using next-generation sequencing and routine HIV RNA genotyping.

2023/6/28

Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection

Nature communications

2023/6/13

Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States

Journal of Virus Eradication

2023/6/1

4th Generation HIV screening in the emergency department: net profit or loss for hospitals?

AIDS care

2023/5/4

Lessons learned from the Last Gift study: ethical and practical challenges faced while conducting HIV cure-related research at the end of life

Journal of medical ethics

2023/5/1

Immunogenicity of the BA. 1 and BA. 4/BA. 5 SARS-CoV-2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial

medRxiv

2023/3/31

Predictors of human immunodeficiency virus pre-exposure prophylaxis (PrEP) uptake in a sexual health clinic with rapid PrEP initiation

Open forum infectious diseases

2023/3/1

Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA. 1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

The Journal of infectious diseases

2023/12/15

Association between where men who have sex with men (MSM) meet sexual partners and chlamydia/gonorrhoea infection before and during the COVID-19 pandemic in San Diego, California

Sexually transmitted infections

2023/12/1

Modeling homophily in dynamic networks with application to HIV molecular surveillance

BMC Infectious Diseases

2023/10/4

Estimating contact network properties by integrating multiple data sources associated with infectious diseases

Statistics in Medicine

2023/9/10

A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life

Pathogens and Immunity

2023

See List of Professors in Susan Little University(University of California, San Diego)